Goldman Sachs Raises Eli Lilly 12-Month Price Target
The pharmaceutical company sees continued growth potential as Medicare coverage for its key weight-loss products expands.
Updated on Oct. 23, 2026 in Economic Indicators
Live Poll
Do you believe now is a good time to invest in major pharmaceutical companies?
Goldman Sachs raised its 12-month price target for Eli Lilly to $1,413, citing strong demand for key weight-loss and therapeutic treatments. This adjustment follows steady growth in prescriptions and revenue across the company's major product lines.
Why it matters
Operators in the pharmaceutical and healthcare sectors should monitor Eli Lilly as a bellwether for consumer demand in the GLP-1 and chronic care markets. The firm's ability to maintain revenue growth while navigating evolving Medicare coverage and pricing strategies offers a benchmark for industry performance.
Goldman Sachs increased its 12-month Eli Lilly price target to $1,413 from $1,371 based on a 28x forward earnings valuation. This comes as the company reports 1.1 million patients covered under Medicare for Zepbound and 535,000 U.S. prescriptions for Foundayo.
The players
Eli Lilly
A global pharmaceutical company focused on the development and commercialization of medicines for chronic conditions including metabolic and autoimmune diseases.
Goldman Sachs
A global investment banking firm that provides institutional research and analysis on market trends and corporate valuations.
The details
The target increase is driven by sustained prescription volumes for Zepbound, Mounjaro, and Foundayo. Eli Lilly is leveraging its expanded Medicare patient base to drive revenue, which hit $23 billion in the second quarter. The firm also modeled earnings per share growth through 2028, underscoring expectations for continued scale in its primary U.S. market.
Timeline
July 1: Medicare coverage for Zepbound began.
September 1: Eli Lilly reduced pricing for Foundayo.
October 29: Eli Lilly is scheduled to report earnings.
December 7: Eli Lilly will hold an investor event.
January: The company expects to provide 2027 financial guidance.
Market Landscape
This development follows recent expansions in Medicare drug coverage policies that have significantly broadened the addressable patient population for GLP-1 therapies. The shift marks a departure from historical access constraints, positioning major pharmaceutical producers to capture higher demand volumes.
Business operators should track the upcoming October 29 earnings report to see if prescription volumes remain consistent with the analyst's growth projections. Companies reliant on the healthcare supply chain should also review the January guidance, which will provide visibility into long-term market stability.
The takeaway
Eli Lilly represents a critical bellwether for the healthcare sector as it scales its patient base through federal programs. Operators should monitor the October 29 earnings release to evaluate whether current market demand projections align with actual reported revenue.
Further reading
For broader trends on corporate valuation and market performance, see Economic Indicators.
Live Poll
Do you believe now is a good time to invest in major pharmaceutical companies?
